Nutex Health Inc. — fact timeline

Nutex Health Inc. reported first quarter ending March 31, 2026 results: revenue $216.5 million, net income $46.8 million, EPS $6.52.

“division ), and a primary care-centric, risk-bearing physician network. Financial highlights for the three months ended March 31, 2026 : • Total revenue increased 2.2% to $216.5 million compared to $211.8 million for the same period in 2025, driven by 1.8% growth in hospital division revenue to $207.6 million from $203.9 million, while revenue at same hospitals,”

Nutex Health Inc. reported fourth quarter and year ending December 31, 2025 results: revenue $151.7 million, net income $11.8 million, EPS $10.48.

“of $185.6 million, and long-term debt, net of $29.2 million. 1 Financial highlights for the three months ended December 31, 2025 : • Total revenue decreased $105.9 million to $151.7 million for the three months ended December 31, 2025 as compared to total revenue of $257.6 million for the same period in 2024, a decrease of 41.1%. • The Company attributes the $105.9”

Nutex Health Inc. reported full year 2025 results: revenue $875.3 million, net income $70.8 million, EPS $10.48.

“on Form 8-K. --- EX-99.1 (EX-99.1) --- NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM FULL YEAR 2025 HIGHLIGHTS: • Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4% • Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1”

Nutex Health Inc. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“October 16, 2025. In the event the Company is not able to file the June 30, 2025 Form 10-Q with the SEC on or before December 12, 2025, the staff of Nasdaq will issue a delisting notice, which the Company may appeal to a Nasdaq Hearings Panel.”

Nutex Health Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “June 30, 2025 Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC. On October 15”

Nutex Health Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“August 20, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “June 30, 2025 Form 10-Q”), with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires the timely filing of all required periodic reports with the SEC. Under Nasdaq r”

Nutex Health Inc. reported that prior financial statements should not be relied upon.

“ber 31, 2024 (the “Original Form 10-K”) (collectively, the “Previously Issued Financial Statements”) treated non-cash obligations related to under-construction and ramping hospitals as equity rather than liabilities and should be restated. The Company does not anticipate any material changes for the first three quarters of interim financial statements for fiscal year 2024. The Company expects that any adjustments related to the treatment of these obligations will be non-cash in nature and have no effect on key financial statement line items such as its revenue, gross profit, liquidity, working capital, short-term and long-term debt, operating cash flow, adjusted EBITDA or number of patient visits as of and for the periods presented therein to be reflected in the fourth quarter of 2024. Accordingly, investors and all other persons should no longer rely upon the Previously Issued Financial”

Nutex Health Inc. engaged Grant Thornton LLP as its auditor.

“The Committee, effective as of May 15, 2025, approved the appointment of Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm”

Nutex Health Inc. dismissed CBIZ CPAs P.C. as its auditor.

“On May 15, 2025, the Committee notified CBIZ CPAs P.C. (“CBIZ”) of its dismissal as the Company’s independent registered public accounting firm”

Nutex Health Inc. engaged CBIZ CPAs P.C. as its auditor.

“On April 25, 2025, with the approval of the Company’s Audit Committee, CBIZ was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”

Marcum LLP resigned as auditor of Nutex Health Inc..

“On April 25, 2025, Nutex Health Inc. (the “Company”) was notified by Marcum that Marcum resigned as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s Audit Committee approved the resignation.”

Nutex Health Inc. reported first quarter 2024 results: revenue $67.5 million, net income Net loss attributable to Nutex Health Inc. of $0.4 million.

“Total revenue of $67.5 million as compared to total revenue of $56.3 million for the three months ended March 31, 2023, an increase of approximately 20%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 6.7% in 2024 compared to 2023. ● Total visits from the Hospital Division were 40,068 for the first quarter 2024 as compared to 33,085 for the first quarter 2023, an increase of 6,983 or 21.1%. Of this visit growth, mature hospitals increased by 5.3% in 2024 compared to 2023. ● Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $5.1 million for the three months ended March 31, 2023.”

Nutex Health Inc.: Certificate of Amendment effecting a 1-for-15 reverse stock split of common stock (effective 2024-04-09).

“On April 9, 2024, the Company filed the Certificate of Amendment with the Delaware Secretary of State to effect the Reverse Split, effective at 11:59 p.m. Eastern Time on April 9, 2024”

Scott J. Saunders was appointed as director at Nutex Health Inc..

“appointed Scott J. Saunders, age 61, to serve as a director of the Company for a term commencing on April 11, 2024”

Nutex Health Inc. reported financial results for the year ended December 31, 2023.

“On March 28, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending December 31, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

Nutex Health Inc. reported financial results for the quarter ending December 31, 2023.

“On March 28, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending December 31, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

Dr. Kelvin Spears was elected as Director at Nutex Health Inc..

“On February 28, 2024, the Board elected Dr. Kelvin Spears, 63, as a member of the Board effective April 1, 2024.”

Dr. Danniel Stites departed as Director at Nutex Health Inc..

“Dr. Danniel Stites informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2023.”

Nutex Health Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2024-01-22).

“On January 22, 2024, the Company entered into a placement agency agreement with Maxim Group LLC (the “Placement Agent”) (the “Placement Agency Agreement”), pursuant to which the Company has agreed to pay the Placement Agent an aggregate fee equal to 7% of the aggregate gross proceeds received by the Company from the sale of the Shares and Warrants in the offering.”

Nutex Health Inc. entered into Securities Purchase Agreement with a single healthcare focused institutional investor valued at approximately $10 million (effective 2024-01-22).

“On January 22, 2024, Nutex Health Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare focused institutional investor for the sale by the Company of 66,666,666 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, and warrants (the “Warrants”) to purchase 66,666,666 shares of the Company’s common stock.”

Nutex Health Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 22, 2023, Nutex Health Inc. (the “Company”) received a letter (the “First Nasdaq Bid Price Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for thirty consecutive business days prior to the date of such letter, the bid price for the Company’s common stock (the “Common Stock”) had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar d”

Nutex Health Inc. reported the three months and nine months ended September 30, 2023 results: revenue $62.7 million, net income Net loss attributable to Nutex Health of $(5.5) million in Q3 2023 and $(14.2) million for the first nine months of 2023.

“is furnished as Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- NUTEX HEALTH reports THIRd quarter 2023 financial results ​ ● NET revenue of $62.7 million ● NET CASH FROM OPERATING ACTIVITIES OF $2.0 MILLION ● Company expects to open FIVE NEW MICRO-HOPITALS IN 2024 ​ HOUSTON, TX − (PRNewswire) – November 9, 2023 – Nutex Health Inc.”

Joshua DeTillio was appointed as Chief Operating Officer at Nutex Health Inc..

“On September 5, 2023, the Company announced the appointment of Joshua DeTillio, age 47, as the Company’s Chief Operating Officer, effective on October 2, 2023 (the "Commencement Date").”

Nutex Health Inc. reported second quarter 2023 results: revenue $58.9 million, net income $3.5 million net loss.

“NUTEX HEALTH reports Second quarter 2023 financial results ​ ● NET revenue of $58.9 million”

Nutex Health Inc.: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to add a provision exculpating certain officers from liability as permitted by Delaware law (effective 2023-06-29).

“add a provision exculpating certain of the Company’s officers from liability in specific circumstances, as permitted by Delaware law.”

Nutex Health Inc.: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 900,000,000 to 950,000,000 (effective 2023-06-29).

“increase the number of authorized shares of our common stock from 900,000,000 to 950,000,000; and”

Nutex Health Inc. shareholders approved Nutex Health Inc. 2023 Employee Stock Purchase Plan at the 2023-06-29 meeting.

“The Nutex Health Inc. 2023 Employee Stock Purchase Plan was approved. For Against Abstain Broker Non-Votes 423,424,537 5,283,394 1,579,423 55,272,241”

Nutex Health Inc. shareholders approved Ratification of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-29 meeting.

“Marcum LLP was ratified as our independent registered public accounting firm for the year ending December 31, 2023: For Against Abstain 438,372,406 43,567,308 3,619,881”

Nutex Health Inc. shareholders approved Amendment to effect reverse stock split at ratio between 1-for-2 and 1-for-15 at the 2023-06-29 meeting.

“An amendment to the Company’s Second Amended and Restated Certificate of Incorporation was approved to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a split ratio of between 1-for-2 and 1-for-15, if and when determined by the Board of Directors in its sole discretion, prior to the one-year anniversary of this Annual Meeting. For Against Abstain 388,368,187 95,908,290 1,283,118”

Nutex Health Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-06-29 meeting.

““3 Years” was approved, on an advisory basis, as the frequency with which the Company should hold future advisory votes on the compensation of the Company’s named executive officers. ​ ​ 3 Years 2 Years 1 Year ​ Broker Non-Votes ​ 332,467,009 2,186,394 95,622,360 ​ ‎‎55,283,832‎”

Nutex Health Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-29 meeting.

“The compensation of our named executive officers was approved, on an advisory basis. For Against Abstain Broker Non-Votes 357,154,478 72,863,958 268,918 ‎55,272,241”

Nutex Health Inc. shareholders approved Amendment to limit liability of officers as permitted by Delaware law at the 2023-06-29 meeting.

“An amendment to our Amended and Restated Certificate of Incorporation to limit the liability of officers of Nutex Health Inc. as permitted by recent amendments to Delaware law was approved. For Against Abstain Broker Non-Votes 370,312,805 55,325,133 4,649,416 ‎55,272,241”

Nutex Health Inc. shareholders approved Amendment to increase authorized shares from 900,000,000 to 950,000,000 at the 2023-06-29 meeting.

“An amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 900,000,000 to 950,000,000 was approved. For Against Abstain 329,679,669 154,683,357 1,196,569”

Nutex Health Inc. shareholders approved Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan at the 2023-06-29 meeting.

“The Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan was approved. For Against Abstain Broker Non-Votes 341,569,765 86,737,458 1,980,131 ‎55,272,241”

Nutex Health Inc. shareholders approved Election of Director Nominees at the 2023-06-29 meeting.

“Each of our director nominees was elected for a term expiring in 2024. Nominee For Withheld Total Broker Non-Votes Thomas T. Vo 397,131,242 33,156,112 ‎‎55,272,241‎ Warren Hosseinion 374,224,778 56,062,576 ‎55,272,241‎ Danniel Stites 414,842,569 15,444,785 ‎55,272,241‎ John Waters 413,165,593 17,121,761 ‎55,272,241‎ Cheryl Grenas 397,331,961 32,955,393 ‎55,272,241‎ Michael L. Reed 397,189,984 33,097,370 ‎55,272,241‎ Mitchel Creem 409,459,787 20,827,567 ‎55,272,241”

Nutex Health Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 22, 2023, Nutex Health Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 20, 2023, t”

Nutex Health Inc. reported first quarter 2023 results: revenue $56.3 million, net income Net loss attributable to Nutex Health of $5.1 million.

“Financial Highlights for the Three Months Ended March 31, 2023: ● Net revenue of $56.3 million. ● Net loss attributable to Nutex Health of $5.1 million.”

Nutex Health Inc. entered into Pre-Paid Advance Agreement (PPA) with YA II PN, Ltd. valued at Up to $25,000,000 initial Pre-Paid Advance, aggregate limit $100,000,000 (effective 2023-04-11).

“On April 11, 2023, Nutex Health Inc. (the “Company”) entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Investor”).”

Dr. Danniel Stites was elected as Director at Nutex Health Inc..

“On April 1, 2023, the Board elected Dr. Danniel Stites, age 42, as a member of the Board.”

Dr. Matthew Young departed as Director at Nutex Health Inc..

“On March 31, 2023, Dr. Matthew Young informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2022.”

Nutex Health Inc. reported the three months ended December 31, 2022 results: revenue $53.7 million, net income Net loss attributable to Nutex Health of $14.7 million.

“Financial Highlights for the Three Months Ended December 31, 2022: ● Total revenue of $53.7 million. ● Net loss attributable to Nutex Health of $14.7 million.”

Nutex Health Inc. reported the fiscal year ended December 31, 2022 results: revenue $219.3 million, net income Net loss attributable to Nutex Health Inc. of $424.8 million.

“99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- ​ ​ NUTEX HEALTH Inc. reports fourth quarter and Full YEAR 2022 financial results ​ ● Total revenue of $219.3 million for the year ended 2022 ● Net cash from operating activities of $50.6 million for the YEAR ended 2022 ● Company expects to open 19 NEW facilities by mid-2025 ​ HOUSTON, TX −”

Nutex Health Inc. reported Nine months ended September 30, 2022 results: revenue $165.6 million, net income $(420.4) million.

“Financial Highlights for the Nine Months Ended September 30, 2022 (Unaudited): • Net revenue of $165.6 million. • Net income attributable to Nutex Health of $(420.4) million.”

Nutex Health Inc. reported Three months ended September 30, 2022 results: revenue $28.4 million, net income $(422.5) million.

“Financial Highlights for the Three Months Ended September 30, 2022 (Unaudited): • Net revenue of $28.4 million. In the three months ended September 30, 2022, we reduced our estimate of the ultimate amounts of accounts receivable we will collect for prior periods. This change in estimate reduced revenue for the three months ended September 30, 2022 by approximately $29 million. • Net income attributable to Nutex Health of $(422.5) million.”

Jon Bates was appointed as Chief Financial Officer at Nutex Health Inc..

“On June 10, 2022, the Company announced the appointment of Jon Bates, age 52, as the Company’s Chief Financial Officer, effective on June 30, 2022”

Michael Bowen departed as Chief Financial Officer at Nutex Health Inc..

“On June 10, 2022, Nutex Health Inc. (the “Company”) announced that Michael Bowen will retire as Chief Financial Officer of the Company.”

Mitchell Creem was elected as Director at Nutex Health Inc..

“In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.”

Michael L. Reed was elected as Director at Nutex Health Inc..

“In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.”

Cherly Grenas was elected as Director at Nutex Health Inc..

“In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.”

John Waters was elected as Director at Nutex Health Inc..

“In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.”